NASDAQ:NTRB Nutriband (NTRB) Stock Price, News & Analysis → The AI Defense Stock Set to Soar (From Behind the Markets) (Ad) Free NTRB Stock Alerts $4.05 +1.01 (+33.22%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$3.44▼$4.2450-Day Range$2.30▼$4.0552-Week Range$1.53▼$5.15Volume500,339 shsAverage Volume32,487 shsMarket Capitalization$31.71 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Nutriband alerts: Email Address Ad Behind the MarketsThe Small Biotech with a BIG Cancer SolutionThere's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.Get the full story here >>> About Nutriband Stock (NASDAQ:NTRB)Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.Read More NTRB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NTRB Stock News HeadlinesMarch 27, 2024 | benzinga.comGerald Goodman's Net WorthMarch 27, 2024 | finanznachrichten.deNutriband Inc.: Nutriband Provides Clinical and Regulatory Path Overview for Lead Product - AVERSA Fentanyl Transdermal PatchMarch 28, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…March 27, 2024 | finance.yahoo.comNutriband Provides Clinical and Regulatory Path Overview for Lead Product - AVERSA(R) Fentanyl Transdermal PatchJanuary 29, 2024 | finance.yahoo.comNutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1stJanuary 26, 2024 | finanznachrichten.deNutriband Inc.: Nutriband CEO Publishes Letter to ShareholdersJanuary 26, 2024 | finance.yahoo.comNutriband CEO Publishes Letter to ShareholdersJanuary 5, 2024 | finance.yahoo.comNutriband Signs Commercial Development and Clinical Supply Agreement With Kindeva Drug Delivery for Aversa(TM) Fentanyl, an Abuse Deterrent Fentanyl PatchMarch 28, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.December 29, 2023 | morningstar.comNutriband Inc NTRBDecember 18, 2023 | investorplace.comNTRB Stock Earnings: Nutriband Reported Results for Q3 2023November 28, 2023 | finance.yahoo.comNutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and CoolingNovember 28, 2023 | finance.yahoo.comNutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and CoolingOctober 11, 2023 | finance.yahoo.comNutriband’s Aversa(TM) Buprenoprhine May Reach Peak Annual Sales of $70-130 Million Based on Market Assessment by Leading Healthcare Consulting FirmSeptember 20, 2023 | finanznachrichten.deFinancialnewsmedia.com: Demand for Abuse Deterrent Formulation Technology Skyrocketing as Opiate Abuse is on the RiseSeptember 20, 2023 | finanznachrichten.deNutriband Inc.: Nutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent TechnologySeptember 20, 2023 | finance.yahoo.comNutriband Unveils Groundbreaking Innovation in Transdermal MedicationsSeptember 20, 2023 | finance.yahoo.comNutriband Announces Issuance of U.S. Patent for Transdermal Abuse Deterrent TechnologySeptember 12, 2023 | finance.yahoo.comNutriband Inc. Receives Five Nominations in the Pharma Industry Awards 2023September 11, 2023 | finance.yahoo.comNutriband Inc. Reports Second Quarter 2023 Financial Results and Provides Business UpdateAugust 30, 2023 | finance.yahoo.comNutriband Inc. Announces Donovan McNabb as AI Tape Brand AmbassadorJuly 28, 2023 | marketwatch.comNutriband Shares Rise 16% After Launch of New Medical Tape ProductJuly 27, 2023 | finance.yahoo.comNutriband Inc. Launches AI Tape Brand Direct-to Consumer OfferingsJuly 14, 2023 | finanznachrichten.deNutriband Inc.: Nutriband Increases Existing Credit Line to $5 Million USD for the Development of its AVERSA Platform Towards FDA SubmissionJuly 14, 2023 | marketwatch.comNutriband Shares Rise 14% After Credit Line Increased to Fund Fentanyl Deterrent TechJuly 14, 2023 | finance.yahoo.comNutriband Increases Existing Credit Line to $5 Million USD for the Development of its AVERSA(TM) Platform Towards FDA SubmissionJune 23, 2023 | finance.yahoo.comNutriband Receives Notice of Allowance for U.S. Patent Covering Transdermal Abuse Deterrent TechnologySee More Headlines Receive NTRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nutriband and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings12/13/2021Today3/27/2024Next Earnings (Estimated)4/24/2024Fiscal Year End1/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical appliances & supplies Sub-IndustryN/A Current SymbolNASDAQ:NTRB CUSIPN/A CIK1676047 Webnutriband.com Phone(407) 377-6695FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,480,000.00 Net Margins-252.90% Pretax Margin-252.90% Return on Equity-73.13% Return on Assets-57.85% Debt Debt-to-Equity Ratio0.37 Current Ratio2.79 Quick Ratio2.54 Sales & Book Value Annual Sales$2.08 million Price / Sales15.25 Cash FlowN/A Price / Cash FlowN/A Book Value$1.09 per share Price / Book3.72Miscellaneous Outstanding Shares7,830,000Free Float4,453,000Market Cap$31.71 million OptionableNot Optionable Beta0.72 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Serguei Melnik (Age 50)Founder, President, Company Secretary & Executive Chairman of the Board Comp: $200kMr. Gareth Sheridan (Age 34)Founder, CEO & Director Comp: $200kMr. Gerald Goodman (Age 76)CFO & Chief Accounting Officer Comp: $160kDr. Alan Smith Ph.D. (Age 58)COO & President of 4P Therapeutics Comp: $179kMr. Patrick Ryan (Age 38)Chief Technical Officer Dr. Jeffrey Patrick Pharm.D. (Age 54)Chief Scientific Officer Mr. Tyler Overk (Age 40)President of Active Intelligence More ExecutivesKey CompetitorsLipocineNASDAQ:LPCNConformisNASDAQ:CFMSTFF PharmaceuticalsNASDAQ:TFFPPredictive OncologyNASDAQ:POAIHeart Test LaboratoriesNASDAQ:HSCSView All CompetitorsInstitutional OwnershipAlphaQ Advisors LLCSold 5,834 shares on 1/29/2024Ownership: 0.149%View All Institutional Transactions NTRB Stock Analysis - Frequently Asked Questions How have NTRB shares performed in 2024? Nutriband's stock was trading at $2.32 at the beginning of 2024. Since then, NTRB shares have increased by 74.6% and is now trading at $4.05. View the best growth stocks for 2024 here. Are investors shorting Nutriband? Nutriband saw a drop in short interest in March. As of March 15th, there was short interest totaling 2,400 shares, a drop of 61.9% from the February 29th total of 6,300 shares. Based on an average daily trading volume, of 16,100 shares, the short-interest ratio is presently 0.1 days. Currently, 0.1% of the shares of the stock are sold short. View Nutriband's Short Interest. When is Nutriband's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024. View our NTRB earnings forecast. How were Nutriband's earnings last quarter? Nutriband Inc. (NASDAQ:NTRB) released its earnings results on Monday, December, 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by $0.11. The firm had revenue of $0.28 million for the quarter, compared to analysts' expectations of $0.50 million. Nutriband had a negative trailing twelve-month return on equity of 73.13% and a negative net margin of 252.90%. When did Nutriband's stock split? Shares of Nutriband split before market open on Monday, August 15th 2022. The 13-6 split was announced on Monday, August 15th 2022. The newly issued shares were distributed to shareholders after the closing bell on Monday, August 15th 2022. An investor that had 100 shares of stock prior to the split would have 217 shares after the split. Who are Nutriband's major shareholders? Nutriband's stock is owned by many different retail and institutional investors. Top institutional investors include AlphaQ Advisors LLC (0.15%). How do I buy shares of Nutriband? Shares of NTRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NTRB) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nutriband Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.